Stockreport

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

PMV Pharmaceuticals, Inc.  (PMVP) 
PDF Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumo [Read more]